Liver cirrhosis can develop for years without obvious symptoms, making it easy to overlook until significant damage has ...
PPAR agonists, antigen-specific immune tolerance therapies and IBAT inhibitors lead the PBC pipeline as companies target patients with an inadequate response to UDCA.Dublin, Oct. (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results